Cutler Group’s Cartesian Therapeutics RNAC Stock Holding History

Cutler Group’s Portfolio RNAC Stock Details RNAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$1K	Hold	57	–	–	﹤0.01%	2091
2023 Q4	$1K	Hold	57	–	–	﹤0.01%	3422
2023 Q3	$1K	Hold	57	–	–	﹤0.01%	3612
2023 Q2	$1K	Hold	57	–	–	﹤0.01%	3385
2023 Q1	$2K	Hold	57	–	–	﹤0.01%	3228
2022 Q4	$1K	Hold	57	–	–	﹤0.01%	4138
2022 Q3	$2K	Hold	57	–	–	﹤0.01%	4279
2022 Q2	$2K	Hold	57	–	–	﹤0.01%	4352
2022 Q1	$2K	Hold	57	–	–	﹤0.01%	4746
2021 Q4	$5K	Hold	57	–	–	﹤0.01%	4223
2021 Q3	$7K	Hold	57	–	–	﹤0.01%	4242
2021 Q2	$7K	Hold	57	–	–	﹤0.01%	4214
2021 Q1	$7K	Buy	57 +4	+8%	+$497	﹤0.01%	4140
2020 Q4	$4K	Sell	53 -37	-41%	-$3.21K	﹤0.01%	3817
2020 Q3	$6K	Buy	+90	New	+$6.9K	﹤0.01%	3387
2019 Q4	–	Sell	-20	Closed	-$1K	–	4497
2019 Q3	$1K	Hold	20	–	–	﹤0.01%	3812
2019 Q2	$1K	Hold	20	–	–	﹤0.01%	3960
2019 Q1	$1K	Sell	20 -34	-63%	-$2.15K	﹤0.01%	3773
2018 Q4	$4K	Buy	+54	New	+$12.3K	﹤0.01%	3062

Other funds holding RNAC

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cutler Group's RNAC Position: Q1 2024 in Review

Cutler Group held its Cartesian Therapeutics (RNAC) position steady in Q1 2024 at 57 shares worth $1K. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

Cutler Group first reported a position in RNAC in Q4 2018 and has held it in 19 quarters since. The position peaked at $7K in Q3 2021. 69 funds tracked by Wall St. Rank hold RNAC as of Q1 2024.

Cutler Group held 57 shares of Cartesian Therapeutics worth $1K as of Q1 2024.
Cutler Group left its Cartesian Therapeutics share count unchanged in Q1 2024.
Cartesian Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #2091 holding.
Cutler Group first reported a position in Cartesian Therapeutics in Q4 2018 and has held it in 19 quarters since.
Cutler Group's Cartesian Therapeutics position peaked at $7K in Q3 2021.
69 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.